

03/08/01

J1050 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	M0656/7063(HCL)
	First Named Inventor or Application Identifier	
	LIU, Dongfang	
	Express Mail Label No.	EL844511027US
Date of Deposit		March 8, 2001

<p style="text-align: center;">APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i></p> <ol style="list-style-type: none"> 1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i> 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> Statement filed in prior application, status still proper and desired. 3. <input checked="" type="checkbox"/> Specification -Total pages 70 - pages description 1 - pages abstract 7 - pages claims 60 - Total claims 4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) - 15 Total sheets <input checked="" type="checkbox"/> Informal <input type="checkbox"/> Formal 15 - Total drawings 5. <input type="checkbox"/> Oath or Declaration - Total pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> <i>[Note Box 6 below]</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18. 7. <input checked="" type="checkbox"/> Application Data Sheet, See 37 CFR 1.76 	<p>ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231</p> <ol style="list-style-type: none"> 8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix) 9. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. <input checked="" type="checkbox"/> Specification Sequence Listing on: <ol style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies
<p>ACCOMPANYING APPLICATION PARTS</p> <ol style="list-style-type: none"> 10. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 12. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i> 13. <input type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 16. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 17. <input type="checkbox"/> Other: _____ _____ 	

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.

Prior application information: Examiner _____ Group Art Unit: _____


For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER **23628** AND (BAR CODE LABEL)

OR

ATTORNEY'S NAME	Helen C. Lockhart, Esq., Reg. No. 39,248				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
NAME Helen C. Lockhart, Esq.	Reg. No. 39,248				
SIGNATURE					
DATE March 8, 2001	March 8, 2001				

Express Mail Label No. EL844511027US

Date of Deposit: March 8, 2001

Attorney Docket No: M0656/7063(HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Liu et al.
Serial No.: Unassigned
Filed: Herewith
For: HEPARINASE III AND USES THEREOF

Box Patent Application
Commissioner for Patents
Washington, D.C. 20231



STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith a copy of the Sequence Listing and a computer readable diskette. Applicants' attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,

Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No. M0656/7063(HCL)
Date: March 8, 2001
X03/08/01